Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Am J Transplant. 2012 Jun 13;12(10):2730–2743. doi: 10.1111/j.1600-6143.2012.04144.x

TABLE 2. Acute clinical and subclinical rejection prevalence according to treatment arm.

This table illustrates how many patients had at least one biopsy with borderline changes, acute T-cell mediated rejection, acute antibody-mediated rejection and chronic antibody-mediated rejection. P-values were obtained using the Chi Square test. The cumulative incidence is reporting on the number of patients who had at least one biopsy with rejection within the given time frame. Patients with more than one biopsy showing rejection were counted once.

Steroid-free treatment group Steroid-based treatment group P value*
Number of patients 60 70
Indication biopsies: associated with graft dysfunction
 Cumulative incidence of acute T-cell mediated rejection
At 1 year 8/60 (13.3%) 8/70 (11.4%) 0.74
At 3 years 10/60 (16.7%) 12/70 (17.1%) 0.94
 Cumulative incidence of borderline changes in patients without T-cell mediated rejection
At 1 year 4/60 (6.67%) 5/70 (7.14%) 0.92
At 3 years 6/60 (10.0%) 8/70 (11.4%) 0.79
 Cumulative incidence of acute T-cell mediated rejection or borderline changes
At 1 year 12/60 (20.0%) 13/70 (18.6%) 0.84
At 3 years 16/60 (26.7%) 20/70 (28.6%) 0.81
 Cumulative incidence of acute antibody-mediated rejection
At 1 year 3/60 (5.00%) 1/70 (1.43%) 0.24
At 3 years 4/60 (6.67%) 1/70 (1.43%) 0.12
 Cumulative incidence of chronic antibody-mediated rejection
At 1 year 0/60 (0.0%) 1/70 (1.43%) 0.35
At 3 years 1/60 (1.67%) 1/70 (1.43%) 0.91
Protocol biopsies: with stable graft function
 Prevalence of subclinical acute T-cell mediated rejection
At 6 months 5/47 (10.6%) 6/53 (11.3%) 0.91
At 12 months 0/35 (0.0%) 2/46 (4.3%) 0.21
At 24 months 0/33 (0.0%) 2/42 (4.8%) 0.20
 Prevalence of subclinical borderline changes
At 6 months 4/47 (8.5%) 5/53 (9.4%) 0.87
At 12 months 6/35 (17.1%) 2/46 (4.3%) 0.06
At 24 months 4/33 (12.1%) 1/42 (2.4%) 0.09
 Prevalence of acute antibody-mediated rejection
At 6 months 0/41 (0.0%) 1/45 (1.89%) 0.34
At 12 months 0/33 (0.0%) 0/42 (0.0%) NA
At 24 months 0/33 (0.0%) 0/39 (0.0%) NA
 Prevalence of chronic antibody-mediated rejection
At 6 months 0/41 (0.0%) 1/45 (1.89%) 0.34
At 12 months 0/33 (0.0%) 0/42 (0.0%) NA
At 24 months 0/33 (0.0%) 0/39 (0.0%) NA
All biopsies (indication and protocol biopsies together)
 Cumulative incidence of acute T-cell mediated rejection
At 1 year 12/60 (20.0%) 15/70 (21.4%) 0.84
At 3 years 14/60 (23.3%) 20/70 (28.6%) 0.50
 Cumulative incidence of borderline changes in patients without acute T-cell mediated rejection
At 1 year 9/60 (15.0%) 8/70 (11.4%) 0.55
At 3 years 11/60 (18.3%) 9/70 (12.9%) 0.39
 Cumulative incidence of acute T-cell mediated rejection or borderline changes
At 1 year 21/60 (35.0%) 23/70 (32.9%) 0.80
At 3 years 25/60 (41.7%) 29/70 (41.4%) 0.98
 Cumulative incidence of acute antibody-mediated rejection
At 1 year 3/60 (5.00%) 2/70 (2.86%) 0.53
At 3 years 4/60 (6.67%) 2/70 (2.86%) 0.30
 Cumulative incidence of chronic antibody-mediated rejection
At 1 year 0/60 (0.0%) 2/70 (2.86%) 0.19
At 3 years 1/60 (1.67%) 2/70 (2.86%) 0.65
 Cumulative incidence of acute or chronic antibody-mediated rejection
At 1 year 3/60 (5.0%) 2/70 (2.86%) 0.53
At 3 years 4/60 (6.67%) 2/70 (2.86%) 0.30